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Intellectual disability (ID) affects approximately 1% of humans with a gender bias towards males. 
Previous studies have identified mutations in over 100 genes on the X chromosome in males with ID, but 
there is less evidence for de novo mutations on the X chromosome causing ID in females. In this study we 
present 34 unique deleterious de novo mutations in DDX3X identified by whole exome sequencing in 37 
females with ID and various other features including hypotonia, movement disorders, behavior 
problems, corpus callosum hypoplasia and epilepsy. Based on our findings, mutations in DDX3X are one 
of the more common causes of ID accounting for 1-2% of unexplained ID in females. 
Although no de novo DDX3X mutations were identified in males, we present three families  with 
segregating missense mutations in DDX3X, suggestive of an X-linked recessive inheritance pattern.  In 
these families males with the DDX3X variant all had ID, while carrier females were unaffected. To explore 
the pathogenic mechanisms accounting for the differences in disease transmission and phenotype 
between affected females and affected males with DDX3X missense variants, we used canonical Wnt 
defects in zebrafish as a surrogate measure of DDX3X function in vivo. We demonstrate a consistent loss 
of function effect of all tested de novo mutations on the Wnt-pathway, and we further show a 
differential effect by gender.  The differential activity possibly indicates a dose dependent effect of 
DDX3X expression in the context of functional mosaic females versus one-copy males, which reflects the 





Intellectual disability (ID) affects approximately 1% of humans with a gender bias towards males.1 
Though mutations causing monogenic recessive X-linked intellectual disability (XLID) have been reported 
in over 100 genes2; 3, the identification of conditions caused by de novo mutations on the X chromosome 
affecting females only, is limited. 4; 5  
 By undertaking a systematic analysis of whole exome sequencing (WES) data on 820 individuals 
(461 males and 359 females) with unexplained ID (from the Department of Genetics Nijmegen, the 
Netherlands), seven de novo variants in DDX3X were identified in females. Given the prominent role of 
de novo mutations in ID6, exome sequencing was performed in the probands and their unaffected 
parents, to identify de novo mutations.7 Exome sequencing and data analysis were performed essentially 
as previously described.8 To replicate these findings, we examined a second cohort of 957 individuals 
(543 males, 414 females) from GeneDx, United States (sequencing methods as previously published9) 
and a third cohort of 4295 individuals (2409 males, 1886 females) from the DDD study10, United 
Kingdom. We identified 12 de novo alleles in the second cohort and 20 de novo alleles in the DDD cohort. 
In total, 39 de novo variants were identified in 2659 females, indicating that mutations at this locus 
contribute as much as 1-2% to unexplained ID in females. No de novo variants in DDX3X were identified 
in males in these three cohorts (Fisher's Exact test: p = 4,815e-9). Additional females with de novo DDX3X 
variants were collected from other clinical and diagnostic centers in the Netherlands, Belgium, Germany, 
Italy and Canada. In this study, we present the clinical and molecular details of in total 37 females from 
the entire collected cohort, who had 34 distinct de novo variants in DDX3X. Of these 34 alleles, 19 alleles 
are predicted to be loss of function alleles (9 frameshift mutations leading to premature stop codon, 6 
nonsense mutations, and 4 splice site mutations producing exon skipping; Table 1), suggesting 
haploinsufficiency as the most likely pathological mechanism. All 14 de novo missense variants are 
located in the Helicase ATP-binding domain or Helicase C-terminal domain (Figure 1).  
 Analysis of the clinical data suggested a syndromic disorder with variable clinical presentation. 
All females (age range 1 - 33 years) showed mild to severe ID or developmental delay with associated 
neurological abnormalities, including hypotonia (28/37, 76%), movement disorders comprising 
dyskinesia, spasticity and a stiff-legged or wide based gait (17/37, 46%), behavior problems including 
autism spectrum disorder (ASD), hyperactivity and aggression (20/37, 54%), and epilepsy (6/37, 16%). 
Several recurrent additional features were noted, including joint hyperlaxity, skin abnormalities (mosaic-
like pigmentary changes in some females), cleft lip and/or palate, hearing and visual impairment and 
precocious puberty. A summary of the clinical data is presented in Table 2 and Supplemental Table 1, 
and facial profiles of 30 of the 37 females are shown in Figure 2. There is no evidence for a diffence in 
clinical  presentation between the frameshift/nonsense mutations and the missense mutations in terms 
of severity of ID.   
 DDX3X is known as one of the genes that are able to escape X-inactivation11; 12.. X-linked 
dominant conditions often show a remarkable variability among affected females which in particular 
holds true for genes that escape X inactivation5; 13. It is known that most of the transcripts escaping X-
inactivation are not fully expressed from the inactivated X-chromosome, which means that the escape is 
often partial and incomplete5.  Based on this, phenotypic severity may be influenced by the amount of 
gene expression of DDX3X  in females, which could be affected by possibly skewed X-inactivation or 
incompleteness of the escape. Different expression of DDX3X in different tissues could also be a 
contributing factor. To further explore this, we determined inactivation using the androgen receptor 
gene (AR) methylation assay14 on DNA from lymphocytes in 15 females and found an almost completely 
skewing (>95%) of X-inactivation in seven individuals and random skewing in the remainder, with no 
evidence of correlation with disease severity. As expected, X-inactivation in females with DDX3X variants 
seems uninformative for the disease phenotype. 
 Given the high frequency (1-2%) of DDX3X mutations in females with unexplained ID, we sought 
to determine whether males carry deleterious alleles. We identified no de novo variants in males in any 
of our cohorts. However, upon sequencing of the X-chromosome (X-exome) of 405 ID families with 
apparent X-linked inheritance pattern3, we identified two families  with segregating missense variants in 
DDX3X. Moreover, one additional family was identified by diagnostic whole exome sequencing in 
Antwerp, Belgium. In these three families males with the DDX3X variant have borderline to severe ID, 
while carrier females are unaffected. Pedigrees of these three families are shown in Supp Figure 1, and a 
summary of the clinical features of the affected males is presented in Supp Table 2. All three missense 
mutations were predicted to be pathogenic by prediction programs PolyPhen 2 and SIFT (Table 1) and 
map within the Helicase ATP-binding domain (Figure 2). With three dimensional protein analysis we 
could not discern any clear difference between the missense mutations found in affected males and the 
de novo mutations found in females that could possibly explain the gender specific pathogenicity (Supp 
Figure 2, Supp Table 3). While in the first two families with affected males the phenotype consisted 
mainly of intellectual disability, family 3 was more complex. The male proband had severe ID and various 
other features such as a dysplastic pulmonary valve, hypertonia and strabismus. His mother had 
recurrent miscarriages of unknown gender. A second initially viable pregnancy was terminated because 
of ultrasound anomalies that had also been noted in the proband, including a thickened nuchal fold and 
absent nasal bone. In retrospect, the male fetus was tested and found to have the same missense 
mutation in DDX3X as his brother. Sequencing of other family members demonstrated the mutation 
arose de novo in the proband’s mother. X-inactivation studies in this mother demonstrated a random X-
inactivation pattern (68/32). X-inactivation studies in female carriers in the other families showed that in 
Family 1 the obligate carrier female (II-2) had highly skewed X-inactivation (>95%), while X-inactivation 
studies in Family 2 were not informative.  
 Neither of the three DDX3X variants found in these families with affected males were reported in 
the ExAC Database or in the Exome Variant Server (ESP), nor was one of the de novo variants found in 
females reported in these databases. We downloaded all variants from the ExAC database, containing 
exome data of 60,706 individuals, and calculated per gene the number of missense and synonymous 
variants. These numbers were then normalized by dividing through the total number of possible 
missense and synonymous variants per gene. The ratio of corrected missense over synonymous variants 
was then used as a measure for tolerance of the gene to normal variation, similar as was done 
previously.15 When genes were ranked according to their tolerance score, DDX3X was among the most 
intolerant genes (1.09% of genes, rank 194 out of 17,856), showing that normal variation in this gene is 
extremely rare.  
 DDX3X encodes a conserved DEAD-box RNA helicase important in a variety of fundamental 
cellular processes that include transcription, splicing, RNA transport and translation.16; 17 DDX3X has been 
associated with many cellular processes, such as cell cycle control, apoptosis and tumorigenesis. 18; 19 It is 
also thought to be an essential factor in the RNAi pathway 20 and it is a key regulator of the Wnt/β-
catenin pathway, acting as a regulatory subunit of CSNK1E and stimulating its kinase activity.21 
 Notably, of the 34 different de novo variants, 19 alleles are predicted to give a loss of function 
effect. Antisense-based knockdown of the DDX3X-orthologue PL10 in zebrafish is already described and 
shows a reduced brain size and head size in zebrafish embryo's at two days post fertilization.10 As 
missense changes in affected females were located in the same protein domain as missense changes in 
affected males, we explored the pathogenic mechanisms accounting for the differences in disease 
transmission and phenotype between affected females and affected males with DDX3X missense 
variants. We therefore employed a combination of in vitro and in vivo assays based on the known role of 
DDX3X in the regulation of Wnt/β-catenin signaling.21 Wnt signaling is a critical developmental pathway; 
the zebrafish is a tractable model in which to study Wnt output 22-27 and to interrogate alleles relevant to 
neurocognitive traits.28 We tested several missense variants, including the female-specific de novo 
variants p.Ile214Thr, p.Arg326His, p.Arg376Cys, p.Ile507Thr, and p.Arg534His as well as the inherited 
variants p.Val300Phe, p.Arg351Gln, and p.Arg362Cys identified in males. A variant from the Exome 
Variant Server (EVS, http://evs.gs.washington.edu/EVS/) encoding p.E196K (rs375996245; MAF <0.002) 
was chosen as a negative control.   
 We first tested whether the missense variants identified in our ID cohort resulted in dominant 
effects by overexpressing either WT or mutant DDX3X human transcript in zebrafish embryos and 
examining the phenotype. Zebrafish (Danio rerio) were raised and mated as described29. Embryos from 
ZDR strain fish were injected into the yolk with 1 nL of solution containing mRNA at the 1-2 cell stage 
using a Picospritzer III microinjector (Parker). Phenotyping was carried out at 2 days post-fertilization 
(dpf). The wild-type (WT) human DDX3X open reading frame (ORF) construct was obtained from the 
Ultimate ORF Collection (LifeTechnologies; clone ID: IOH13891), sequenced fully and sub-cloned into the 
pCS2+ vector using Gateway LR clonase II- mediated cloning (LifeTechnologies). Capped mRNA was 
generated using linearized constructs as a template with the mMessage mMachine SP6 transcription kit 
(LifeTechnologies).  Injection of 100 pg of WT or mutant DDX3X transcripts did not produce a discernible 
phenotype at 36 hours post fertilization (hpf) (n=50-75 embryos/injection; repeated twice with masked 
scoring; Supp Figure 3A) or at 72 hpf (not shown). To corroborate these data in a different system, we 
used a mammalian cell-based assay of canonical Wnt signaling (TOPFlash).30 Briefly, HEK293T cells and 
mouse L-cells (both control and Wnt3a expressing) were grown in 10% FBS/DMEM. Wnt3a containing 
media was prepared by incubating confluent L-cells with serum-free media for 24 hours, removing and 
filtering the media. This was subsequently used to stimulate transfected HEK293T cells. HEK293T cells at 
a density of 1x104 cells/well of 24-well plate were transfected with  
g of pGL4.18 TOPFLASH vector, 25 ng of renilla luciferase plasmid (pRL-SV40), and 0.5 g of pCS2+ with 
or without DDX3X using XtremeGene9 (Roche). After 24 hours the media was removed and replaced 
with serum-free media collected as above from L-cells with and without WNT3A. After 24 hours cells 
were harvested and luciferase activity measured using the Dual-Luciferase Reporter Assay System 
(Promega). Results were normalized internally for each well to renilla luciferase activity and then to the 
unstimulated wells (conditioned with control L-cell media). Consistent with the in vivo result, 
transfection of expression constructs harboring DDX3X variants did not differ from WT in the modulation 
of WNT3A--catenin mediated luciferase activity (Supp Figure 3B; triplicate wells with 3-5 biological 
replicates). Taken together, our results suggest that neither the female nor the male DDX3X variants 
produce detectable dominant changes in the context of Wnt-signaling. As a consequence, we then 
pursued a loss of function paradigm. 
 Previous studies have shown that co-expression of a canonical Wnt ligand and DDX3X is 
necessary to produce a phenotype in vivo.21 Expression of either of the canonical Wnt ligands WNT3A or 
WNT8A results in ventralization of zebrafish embryos that ranges from mild (hypoplasia of the eyes, 
which we term Class I embryos) to moderate (absence of one or both eyes; Class II), severe (loss of all 
anterior neural structures; Class III), and radialized phenotypes at 2 days post fertilization (dpf) (Class 
IV).24 We recapitulated these defects by injecting increasing doses of human WNT3A or WNT8A mRNA 
into embryos (Figure 3A, 3B). Full-length human WNT3A and WNT8A ORFs were cloned into pCS2+ from 
the Ultimate ORF Collection (Clone ID WNT8A: IOH35591; Clone ID WNT3A: IOH80731). The WNT3A 
clone required site-directed mutagenesis to introduce a stop codon using primers 
(ctgcaaggccgccaggcacTAGGGTGGGCGCGCCGA and its reverse complement). We selected a dose of 
WNT3A mRNA (200 fg), which produced a modest effect (15-20% Class I+II embryos, no Class III or IV) 
and we co-injected it with progressively increasing concentrations of human DDX3X mRNA. At 2 dpf, we 
observed a dose-response curve concomitant with increasing doses of DDX3X (Figure 3D). At low doses 
of mutant DDX3X (15-20 pg/embryo), the ventralization phenotype produced by WNT3A is exacerbated, 
producing 40-50% Class I+II embryos, with a greater percentage in class II (10-15%), indicative of 
augmented severity (Figure 3D). 
 Because of the significant (p<0.0001) augmentation of WNT3A-mediated ventralization at 15 pg 
of DDX3X, we next used this combination of doses to test the effect of the missense alleles on Wnt 
signaling. WNT3A mRNA (200 fg) was co-injected with 15 pg of WT or variant DDX3X mRNA, and we 
scored embryos for ventralization at 2 dpf. We found differential effects of the variants on ventralization 
(Figure 3E; triplicate experiments; pooled for the final result). All de novo variants tested were 
significantly different from WT (p<0.001) and indistinguishable from WNT3A alone, suggesting that they 
all confer complete loss of function to DDX3X. By contrast, the control variant p.E196K, resulted in 
phenotypes similar to WT. Notably, all three inherited variants found in the male patients were also 
indistinguishable from WT-injected, and each was statistically different from WNT3A alone (p<0.0001). 
Given this apparent dichotomization of effect between female de novo and male inherited alleles, we 
tested whether pooling of results from the female versus male variants would exhibit a “class effect” 
separation between the two groups. We found this to be true; there was significant differential effect of 
the gender-specific sets of variants on Wnt signaling (Figure 3F). 
 Taken together, our in vivo testing of the nonsynonymous DDX3X mutations demonstrated 
marked alteration in Wnt-mediated ventralization for changes arising de novo in affected females. Our 
data also reinforce the notion that disruption of -catenin signaling during neurodevelopment has 
profound consequences. Loss of Wnt-signaling inhibits neuroblast migration, neural differentiation, and 
suppression of the development of the forebrain.31-34 Moreover, we previously reported that mutations 
in -catenin contribute to ID in humans35; 36, while mutations in -catenin, some of which abrogate its 
biochemical interaction with -catenin, can contribute to severe autism in females28, strengthening 
further the link between WNT-signaling and human neurodevelopmental disorders. 
DDX3X has recently been proposed as a candidate ID gene.10; 37 Our data substantiate this 
hypothesis and suggest that mutated DDX3X is amongst the most common causes of sporadic 
intellectual disability in females. Our data also suggest that the genetic architecture of DDX3X-mediated 
pathology in males is different. All detected male alleles were inherited from unaffected mothers, 
suggesting either a gender specific buffering effect or a milder effect of those inherited alleles on protein 
function. Both our in vivo and our in vitro studies indicate that none of the tested alleles (male or female) 
confer dominant effects and that the male alleles are indistinguishable from WT in our system. Given 
that human genetics and computational predictions support the causality of these alleles in the families 
studied, we speculate that the effect of these alleles is beyond the dynamic range of our assays and 
could thus not be detected; a substantially larger assay of embryos might detect a signal, although the 
transient nature of our system will always be limited at detecting mild allele effects. Alternatively, the 
mechanism of the male-derived alleles might be qualitatively different from the de novo female variants 
and reflective of the complex biology of DDX3X. Of note, we found that increased amounts of wild type 
DDX3X ameliorated the Wnt3a-induced ventralization phenotype (Supp Figure 4B), an observation that 
we reproduced with Wnt8a, another -catenin-dependent ligand (Supp Figure 4A) and our TOPFlash 
reporter assay (Supp Figure 3B). This bimodal activity of DDX3X has been intimated previously by Cruciat 
et.al., in which knockdown of DDX3X caused loss of WNT3A signaling which was restored by transfection 
with WT construct while overexpression alone resulted in decreased WNT3A signaling.21 We reproduced 
this latter finding when solely overexpressing DDX3X in HEK293 cells (Supp Figure 3B).  
 Summarized, these data suggest that DDX3X is dosage-sensitive and may have a differential 
activity in females versus males. Contribution of the DDX3X homologue at the Y-chromosome, DDX3Y, to 
phenotypic variability is unlikely.38 DDX3X and DDX3Y have 92% amino acid sequence in common11 but 
DDX3Y is translated only in spermatocytes and is essential for spermatogenesis.39; 40 Men with a deletion 
of DDX3Y have severe testicular pathology but no cognitive dysfunction or other reported 
abnormalities.40  
 In conclusion, de novo variants in DDX3X are a frequent cause of intellectual disability, affecting 
1-2% of all so far unexplained ID in females. While no de novo mutations were identified in males, we 
found missense variants in DDX3X in males from three families with ID suggestive of X-linked recessive 
inheritance. Our phenotypic read out in zebrafish shows a gender difference in identified variants with a 
loss of function effect of all tested de novo mutations on the Wnt-pathway. The differential activity 
possibly indicates a dose dependent effect of DDX3X expression in the context of functional mosaic 
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  Nucleotide change Amino acid change SIFT PolyPhen2 
Females Individual 1 c.1126C>T Arg376Cys 0.00 1.000 
 
Individual 2 c.233C>G Ser78* NA NA 
 
Individual 3 c.1126C>T Arg376Cys 0.00 1.000 
 
Individual 4 c.136C>T Arg46* NA NA 
 
Individual 5 c.1601G>A Arg534His 0.00 1.000 
 
Individual 6 c.641T>C Ile214Thr 0.01 0.998 
 
Individual 7 c.1520T>C Ile507Thr 0.00 0.995 
 
Individual 8 c.977G>A Arg326His  0.00 1.000 
 
Individual 9 c.868del Ser290Hisfs*31 NA NA 
 
Individual 10 c.1229_1230dup Thr411Leufs*10 NA NA 
 
Individual 11 c.1105dup Thr369Asnfs*14 NA NA 
 
Individual 12 c.865-2A>G p. (?) NA NA 
 
Individual 13 c.1600dup Arg534Profs*13 NA NA 
 
Individual 14 c.269dup Ser90Argfs*8 NA NA 
 
Individual 15 c.1440A>T Arg480Ser 0.00 0.991 
 
Individual 16 c.873C>A Tyr291* NA NA 
 
Individual 17 c.1693C>T Gln565* NA NA 
 
Individual 18 c.1535_1536del His512Argfs*5 NA NA 
 
Individual 19 c.766-1G>C p.(?) NA NA 
 
Individual 20 c.599dup Tyr200* NA NA 
 
Individual 21 c.1321del Asp441Ilefs*3 NA NA 
 
Individual 22 c.1383dup Tyr462Ilefs*3 NA NA 
 
Individual 23 c.1384_1385dup His463Thrfs*34 NA NA 
 
Individual 24 c.1535_1536del  His512Argfs*5 NA NA 
 
Individual 25 c.1541 T>C Ile514Thr 0.00 1.000 
 
Individual 26 c.704 T>C Leu235Pro 0.00 1.000 
 
Individual 27 c.1175 T>C Leu392Pro 0.00 1.000 
 
Individual 28 c.1463 G>A Arg488His 0.00 0.844 
 
Individual 29 c.1126 C>T Arg376Cys 0.00 1.000 
 Individual 30 c.1250 A>C Gln417Pro 0.00 1.000 
 Individual 31 c.698C>T Ala233Val 0.02 1.000 
 Individual 32 c.931C>T Arg311* NA NA 
 Individual 33 c.46-2A>C p.(?) NA NA 
 Individual 34 c.1678_1680del Leu560del NA NA 
 Individual 35 c.1423C>G Arg475Gly 0.04 0.998 
 Individual 36 c.46-2A>G p.(?) NA NA 
 Individual 37  c.1703C>T Pro568Leu 0.00 1.000 
Males Family 1 c.1084C>T Arg362Cys 0.00 1.000 
 
Family 2 c.1052G>A Arg351Gln 0.00 0.865 
 
Family 3 c.898G>T Val300Phe 0.02 1.000 
  
Table 2: Clinical features of females with de novo DDX3X mutations   
Development Percentage Number 
Intellectual disability or developmental delay 100% 37/37 
  Mild or Mild-Moderate 27% 10/37 
  Moderate or Moderate-Severe 27% 10/37 
  Severe  38% 14/37 
  Developmental delay 8% 3/37 
Growth     
Low weight 32% 12/37 
Microcephaly 30% 11/37 
Neurology     
Hypotonia 76% 28/37 
Epilepsy 16% 6/37 
Movement disorder 46% 17/37 
Behavior problems 54% 20/37 
Brain MRI     
Corpus callosum hypoplasia 36% 13/36 
Cortical malformation 11% 4/36 
Ventricular enlargement 36% 13/36 
Other     
Skin abnormalities 38% 14/37 
Hyperlaxity 35% 13/37 
Visual problems 35% 13/37 
Hearing loss 8% 3/37 
Cleft lip or palate 8% 3/37 
Precocious puberty 14% 5/37 
Scoliosis 11% 4/37 
 
Figure 1: Location of amino acid substitutions in DDX3X protein 
 
Location of amino acid substitutions in DDX3X protein sequence. The DDX3X protein consists of two 
subdomains: a N-terminal domain 1 and a C-terminal domain 2. All amino acid variants found in affected 
females are located within these two protein domains. The three amino acid substitutions found in 
affected males are all located within the Helicase ATP-binding domain. 
  
Figure 2: Facial profiles of females with de novo DDX3X mutations  
 
Facial features of 30 of 37 females with a de novo variant in DDX3X. Common facial features include a 
long and sometimes hypotonic face (e.g. individuals 2, 4, 5, 12, 22, 32), a high and/or broad forehead 
(e.g. individuals 1, 7, 9, 23 , 24, 26), a wide nasal bridge and/or bulbous nasal tip (e.g. individuals 11, 13, 
15, 16), narrow alae nasi and/or anteverted nostrils (e.g. individuals 2, 8, 9, 12, 14, 18, 24, 27, 32, 35) and 
hypertelorism (e.g. individuals 5, 7, 8, 20, 27). Informed consent was obtained for all 30 individuals 




Figure 3 The effect of wildtype and variant DDX3X mRNA on WNT3A-mediated ventralization  
 
Zebrafish embryos at two days post fertilization (dpf) either uninjected (A) or injected with human 
WNT3A without (B) or with (C) human DDX3X show a range of ventralized phenotypes. These were 
scored according to Kelly et. al. 24 as normal, Class I, or Class II ventralization. No injection condition 
resulted in severe ventralization (Class III or IV).   
 (D) Co-injection of WNT3A and DDX3X shows an augmentation of WNT3A mediated ventralization with 
increasing dose up to 15pg. (E) Individual variants of DDX3X were tested for their effect on increasing 
WNT3A mediated ventralization using 200fg of WNT3A mRNA and 15pg of DDX3X mRNA per embryo 
(dose of maximal response from (D)). Scoring is the same as in (D). The female de novo variants and the 
male familial variants are shown together. The mutation E196K is a rare allele from the Exome Variant 
Server (EVS). The red horizontal line delineates a division between those variants which behave as “wild-
type” (e.g. the male variants and E196K) and those that do not. All female de novo variants are 
significantly different from wild-type. *p < 0.001 compared with WNT3A + wild-type DDX3X co-injection. 
#p < 0.0001 vs. WNT3A alone. (F) Graph illustrating the effect of combining the results from the female 
de novo variants and comparing to the male familial variants and to the E196K variant from the EVS. 
There is clear segregation of effect based on the source of the genetic variant. **p < 0.0001 vs. WNT3A + 
wild-type DDX3X. ##p< 0.0001 vs. WNT3A alone. For each graph total (n) is shown at the bottom of each 
bar.  
 
 
